What question did this study set out to answer?

To examine the regulatory role of the gut microbiome in modulating response to immune checkpoint inhibitor therapy and the development of immune-related colitis.

August 28, 2023Intestinal ResearchOpen Access

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review

View Full Paper

Ask AI

Bookmark

Authors

SHSung Wook HwangUlsan College MKMin Kyu KimUlsan College MKMi‐Na KweonUlsan College

Discussion

Member takes

Implication

Review highlights gut microbiota influence on immune checkpoint inhibitor response and colitis in cancer, suggesting microbial manipulation may reduce toxicity and boost anti-tumor immunity.

Key Points

To examine the regulatory role of the gut microbiome in modulating response to immune checkpoint inhibitor therapy and the development of immune-related colitis.
Synthesized literature on gut microbiota variations and their interactions with host immunity and cancer therapy outcomes.
Evaluated interventions altering gut microbial composition, specifically fecal microbiota transplantation and probiotics, aimed at managing immunotherapy toxicities.
Distinct bacterial species in the gut microbiota correlate with cancer outcomes and predict therapeutic responsiveness to immune checkpoint inhibitors.
Immune-related colitis represents a frequent adverse event that can disrupt or force the cessation of effective immunotherapy regimens.
Microbiome modulation via fecal microbiota transplantation or probiotics shows promise in dampening colitis severity while preserving anti-tumor immune activity.

Cite This Study

Hwang et al. (2023) studied this question.

synapsesocial.com/papers/6a013dee6be84a7ac885a5f8 https://doi.org/10.5217/ir.2023.00019

View Full Paper

Ask AI

Bookmark

August 28, 2023Intestinal ResearchOpen Access

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review

View Full Paper

Ask AI

Bookmark

Authors

SHSung Wook HwangUlsan College MKMin Kyu KimUlsan College MKMi‐Na KweonUlsan College

Discussion

Member takes

Implication

Review highlights gut microbiota influence on immune checkpoint inhibitor response and colitis in cancer, suggesting microbial manipulation may reduce toxicity and boost anti-tumor immunity.

Key Points

To examine the regulatory role of the gut microbiome in modulating response to immune checkpoint inhibitor therapy and the development of immune-related colitis.
Synthesized literature on gut microbiota variations and their interactions with host immunity and cancer therapy outcomes.
Evaluated interventions altering gut microbial composition, specifically fecal microbiota transplantation and probiotics, aimed at managing immunotherapy toxicities.
Distinct bacterial species in the gut microbiota correlate with cancer outcomes and predict therapeutic responsiveness to immune checkpoint inhibitors.
Immune-related colitis represents a frequent adverse event that can disrupt or force the cessation of effective immunotherapy regimens.
Microbiome modulation via fecal microbiota transplantation or probiotics shows promise in dampening colitis severity while preserving anti-tumor immune activity.

Cite This Study

Hwang et al. (2023) studied this question.

synapsesocial.com/papers/6a013dee6be84a7ac885a5f8 https://doi.org/10.5217/ir.2023.00019

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark